Vis enkel innførsel

dc.contributor.authorZhu, Geyunjian Harry
dc.contributor.authorAzharuddin, Mohammad
dc.contributor.authorIslam, Rakibul
dc.contributor.authorRahmoune, Hassan
dc.contributor.authorDeb, Suryyani
dc.contributor.authorKanji, Upasona
dc.contributor.authorDas, Jyotirmoy
dc.contributor.authorOsterrieth, Johannes
dc.contributor.authorAulakh, Parminder
dc.contributor.authorIbrahim-Hashi, Hashi
dc.contributor.authorManchanda, Raghav
dc.contributor.authorNilsson, Per
dc.contributor.authorMollnes, Tom Eirik
dc.contributor.authorBhattacharyya, Maitreyee
dc.contributor.authorIslam, Mohammad Mirazul
dc.contributor.authorHinkula, Jorma
dc.contributor.authorSlater, Nigel K. H.
dc.contributor.authorPatra, Hirak K.
dc.date.accessioned2022-01-12T09:08:01Z
dc.date.available2022-01-12T09:08:01Z
dc.date.issued2021-05-12
dc.description.abstractNanomedicine is seen as a potential central player in the delivery of personalized medicine. Biocompatibility issues of nanoparticles have largely been resolved over the past decade. Despite their tremendous progress, less than 1% of applied nanosystems can hit their intended target location, such as a solid tumor, and this remains an obstacle to their full ability and potential with a high translational value. Therefore, achieving immune-tolerable, blood-compatible, and biofriendly nanoparticles remains an unmet need. The translational success of nanoformulations from bench to bedside involves a thorough assessment of their design, compatibility beyond cytotoxicity such as immune toxicity, blood compatibility, and immune-mediated destruction/rejection/clearance profile. Here, we report a one-pot process-engineered synthesis of ultrasmall gold nanoparticles (uGNPs) suitable for better body and renal clearance delivery of their payloads. We have obtained uGNP sizes of as low as 3 nm and have engineered the synthesis to allow them to be accurately sized (almost nanometer by nanometer). The synthesized uGNPs are biocompatible and can easily be functionalized to carry drugs, peptides, antibodies, and other therapeutic molecules. We have performed <i> in vitro </i> cell viability assays, immunotoxicity assays, inflammatory cytokine analysis, a complement activation study, and blood coagulation studies with the uGNPs to confirm their safety. These can help to set up a long-term safety-benefit framework of experimentation to reveal whether any designed nanoparticles are immune-tolerable and can be used as payload carriers for next-generation vaccines, chemotherapeutic drugs, and theranostic agents with better body clearance ability and deep tissue penetration.en_US
dc.description.sponsorshipEUen_US
dc.identifier.citationZhu, Azharuddin, Islam, Rahmoune, Deb, Kanji, Das, Osterrieth, Aulakh, Ibrahim-Hashi, Manchanda, Nilsson, Mollnes, Bhattacharyya, Islam, Hinkula, Slater, Patra. Innate Immune Invisible Ultrasmall Gold Nanoparticles - Framework for Synthesis and Evaluation. ACS Applied Materials & Interfaces. 2021en_US
dc.identifier.cristinIDFRIDAID 1916578
dc.identifier.doi10.1021/acsami.1c02834
dc.identifier.issn1944-8244
dc.identifier.issn1944-8252
dc.identifier.urihttps://hdl.handle.net/10037/23667
dc.language.isoengen_US
dc.publisherAmerican Chemical Societyen_US
dc.relation.journalACS Applied Materials & Interfaces
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/706694/United Kingdom/Theranostic molecular zipper based switchable nanomedicine for overcoming drug resistance/NinZa/en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright © 2021 American Chemical Societyen_US
dc.titleInnate Immune Invisible Ultrasmall Gold Nanoparticles - Framework for Synthesis and Evaluationen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel